Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb 1Q

Eliquis sales soar to $355 million

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb

1Q Revenues: $4.0 billion (+4%)

1Q Earnings: $1.2 billion (+27%)

Comments: U.S. revenues were up 16% to $2.0 billion in the quarter. International revenues decreased 2% to $2.0 billion. Eliquis sales were $355 million, up from $106 million in 1Q14. Yervoy sales were up 20% to $325 million. Orencia and Sprycel grew 10% to $400 million and $375 million, respectively. Daklinza and Sunvepra had combined sales of $264 million and Opdivo had sales of $40 million. R&D expenses were up 7% to $1.0 billion in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters